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septal: 97.6%; p¼ns) and procedural complication (AV groove 4.1%,
epicardial 4.8%, septal 2.4%; p¼ns) rates were achieved in the 3
subgroups.
CONCLUSIONS In real world retrograde CTO PCIs, selection of
collateral channel guided by a proposed hierarchic decision algorithm
achieved high technical success rate and low procedural complication
rate. With liberal but rational selection, AV groove, epicardial, or
septal collateral channels may all be used with similar technical suc-
cess and procedural complication rates.
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BACKGROUND Bifurcation treatment using the provisional strategy
with routine ﬁnal kissing balloon dilatation (FKBD) have resulted in
longer and more complex procedures compared to a strategy of no
FKBD. FKBD may reduce delayed strut coverage and ﬂow limiting
neointimal growth on stent struts jailing the side branch ostium.
However, stent distortion after FKBD may negatively affect vessel
healing. We present the 5-year clinical follow-up in the Nordic-Baltic
Bifurcation Study III (NCT00914199) on routine vs. no FKBD.
METHODS 477 patients with a bifurcation lesion were randomized to
FKBD (n¼238) or no-FKBD (n¼239) after main vessel stenting. The 6-
month primary end-point was a composite of major adverse cardiac
events (MACE); cardiac death, non-procedure related index lesion
myocardial infarction, target lesion revascularization or deﬁnite stent
thrombosis.
RESULTS Five-year follow-up was available in 472 (99%) patients.
The 5-year MACE rate was 14.5% in the FKBD group compared to 13.1%
(p¼0.66) in the no-FKBD group. All-cause mortality was observed in
9.8% vs. 3.8% (p¼0.01), cardiac death in 4.2% vs. 0.8% (p¼0.02), non-
procedural myocardial infarction in 4.3% vs. 4.7% (p¼0.83), target
lesion revascularization in 8.5% vs. 10.1% (p¼0.55), and deﬁnite stent
thrombosis in 0.8% vs. 1.3% (p¼0.66) of patients in the FKBD and no-
FKBD groups, respectively. In the subgroup of true bifurcation lesions
(n¼235) 5-year MACE rates were 16.0% in the FKBD group vs. 18.1%
(p¼0.66) in the no-FKBD group.
CONCLUSIONS A strategy of routine FKBD compared to no FKBD, in
main vessel-only stenting did not improve 5-year clinical outcome
after treatment of coronary bifurcation lesions. Cardiac mortality and
all-cause mortality were signiﬁcantly increased in the routine FKBD
group at 5 years.
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BACKGROUND Balloon pulmonary angioplasty (BPA) is an emerging
therapeutic method in CTEPH. We aimed to prove the safety and ef-
ﬁcacy of reﬁned BPA driven by combined assessment of intra-arterial
anatomy (IVUS/OCT) and physiology (pulmonary pressure ratio, PPR)
in non-operable distal CTEPH.
METHODS 11 pts (mean age 76, 59-84, 7males) were enrolled in the BPA
program according to the following inclusion criteria: 1. Non-operable
CTEPH; 2. RHC with mPAP >30mmHg; 3. At least one segmental
perfusion defect at lung scintigraphy; 4. WHO class > II. Overall, 9 pts
underwent 27 BPA sessions, 50 pulmonary arteries were dilated (mean
6 vessels per patient, range 3-9; 2.03 dilated arteries per session). All the
angioplasties were performed according to an algorithm, which incor-
porated anatomical and functional assessment of targeted lesions.
RESULTS We performed BPA of 32 web lesions, 5 ring-like stenosis
and 13 complete obstructions. BPA resulted in clinical and hemody-
namic improvement. WHO class improved from pre-BPA to post-BPA
(p¼0.011), and 6 MWD increased from 304m to 384m (p ¼0.03), NT-
proBNP dropped from 1248 pg/ml to 730pg/ml (p¼0.007). Mean PAP
and PVR decreased (p¼0.01), while CO and CI increased (p¼0.01). All
dilated arteries were patent at angiographic reassessment. No signif-
icant complications occurred and all treated patients are still alive.
Insigniﬁcant transient reperfusion pulmonary edema (RPE) occurred
in only 2 patients, who responded well to supplemental oxygen.
CONCLUSIONS BPA with assessment of intrapulmonary physiology
using a pressure wire and precise evaluation of anatomy with IVUS
and OCT provides hemodynamic and functional improvement, with
minimal complications in distal non-operable CTEPH. This observa-
tion requires further validation in a large prospective study.
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BACKGROUND Pulmonary vein stenosis (PVS) is a rare, but serious
complication of pulmonary vein isolation resulting in debilitating
symptoms including cough, chest pain, dyspnea, hemoptysis, and
pulmonary infarction. Despite advances in interventional techniques,
re-stenosis after PV dilation and/or stenting is a signiﬁcant and
common complication with no conclusive data regarding recurrence
with balloon angioplasty versus stenting. We sought to ascertain the
incidence of PVS recurrence after an initially successful intervention,
and evaluate procedural characteristics which might have prognostic
implications on predicting future restenosis.
METHODS We abstracted baseline demographic data, date and
method of PVS diagnosis, and presenting symptoms on patients who
underwent an incident PVS intervention between November 2000 and
November 2014. We charted PVS interventional procedural data
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method of intervention, complications, and recurrence.
RESULTS Of the 112 patients who went to the lab, we analyzed data
encompassing 216 veins with 39 veins not intervened upon secondary
to complete occlusion or lack of substantial PV-LA pressure gradient.
After an initial 94% procedural success rate, there were 76 PVS re-
currences (44%) over a median follow up time of 4.6 years. We found
those who experienced PVS recurrence had signiﬁcantly higher post-
procedure PV/LA gradients (3.84.9 mmHg vs 1.71.8 mmHg,
p¼0.001) compared to those who avoided recurrence. Patients who
underwent initial stenting compared to balloon dilatation had a 44%
reduction in recurrence compared to those who underwent balloon
dilatation only (RR¼0.56, 95% CI 0.41 to 0.75, p<0.0001, Figure 1). We
also note signiﬁcantly higher balloon atmosphere inﬂations among
patients who did not recur (9.14.0 atm vs 7.32.3 atm, p¼0.007) with
no difference in pre-procedural lesion characteristics or stent/balloon
size.
CONCLUSIONS These results demonstrate PVS recurrence is com-
mon, and is more likely to occur over a lengthy follow up in those
who initially underwent balloon dilatation compared to stenting.
Furthermore, difﬁcult lesions where higher balloon insufﬂation
cannot be achieved resulting in higher post-procedure PV/LA gradi-
ents are more likely to result in recurrence. Thus, PVS should be
initially treated with stenting to avoid further sequelae of PVI such as
recurrent PVS.
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BACKGROUND Optimal therapeutic strategies for patients with
atrial septal defect (ASD) complicated with severe pulmonary arte-
rial hypertension (PAH) is controversial. Combination of recent
advanced PAH speciﬁc medication and transcatheter ASD closure
may contribute the improvement of therapeutic outcome in these
difﬁcult patients population. Our purpose was to evaluate the efﬁ-
cacy of PAH-speciﬁc medications combined with transcatheter
closure.
METHODS Between January 2006 and December 2013, 780 patients
with ASD were performed transcatheter closure, and 48 of 780 pa-
tients (6.2%) complicated with PAH (mean pulmonary artery
pressure  25 mm Hg). Following patients were excluded from thisstudy because of pulmonary hypertension related to lung diseases
(n¼8), left ventricular systolic dysfunction (n¼1) and pulmonary em-
bolism (n¼1). Among 38 patients with PAH associated with ASD, 3
patients excluded because the defects was too large for device
deployment. A total of 35 patients underwent successful procedures
and were included in this study. Among of these, 8 patients with se-
vere PAH required of PAH-speciﬁc medication (PAH speciﬁc group)
and compared to 40 patients who did not required of PAH-speciﬁc
medication (non PAH-speciﬁc group) were studied. PAH-speciﬁc
medications included an endothelin receptor antagonist (bosentan;
n ¼ 4), a phosphodiesterase type-5 inhibitor (sildenaﬁl; n ¼ 4), an oral
prostanoid (beraprost; n ¼ 1), and an intravenous prostanoid (epo-
prostenol; n ¼ 2).
RESULTS After the induction of PAH speciﬁc medication (mean 6.6
months), transcatheter ASD closure was successfully performed in all
without hemodynamic intolerances. Mean device size was 26  7 mm
and the mean ﬂuoroscopic time was 15  8 min. Multiple devices were
required in 2 patients. No hemodynamic compromise occurred in any
of the patients during or after the procedure. Improvement of systolic
PAP was signiﬁcantly greater in PAH-speciﬁc group compared to non
PAH-speciﬁc group (median, 49; range, 26 to 105 mm Hg vs. median,
14; range 4 to 77 mm Hg, respectively; p ¼ 0.0014). Among 29 patients
with symptomatic heart failure, improved heart failure symptoms was
observed in 21 (72%) patients with no exacerbation of heart failure.
Compared with the initial evaluation, BNP levels signiﬁcantly
improved at follow-up at follow-up period (p ¼ 0.0017). During the
mean observational period of 45  25 months, one patient required
hospital admission due to the progression of sick sinus syndrome. No
other adverse events including hospitalization of exacerbation of PAH
were observed.
CONCLUSIONS Even in patients with severe PAH, who initially did
not fulﬁll the indication of transcatheter ASD closure, the recent PAH
speciﬁc medication can contribute the signiﬁcant improvement of
hemodynamic condition. This treat and repair strategies may expand
of therapeutic indication for transcatheter ASD closure in patients
with severe PAH.
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BACKGROUND Transcatheter closure of large post-tricuspid shunts
in patients with severe pulmonary arterial hypertension (PAH) re-
mains a challenging clinical problem. In neonates and infants it is
most often reversible, but in older patients the resolution of PAH
is variable depending on the reversibility of pulmonary vascular
resistance. The current study was done to assess the safety and ef-
ﬁcacy of percutaneous device closure of large post tricuspid
shunts in pediatric patients with severe PAH at short and mid term
follow up.
METHODS A total of 42 pediatric patients underwent transcatheter
closure of large post tricuspid shunts with severe PAH. All subjects
underwent clinical examination, electrocardiography, chest x-rays
and echocardiography before discharge and at 1, 6 and 12 months after
the procedure and yearly thereafter for 5 years.
RESULTS Type of defect was ventricular septal defect in 8 patients
(19%), patent ductus arteriosus in 27 patients (64%), aorto-pulmonary
window in 5 patients (12%) and coronary cameral ﬁstula in two pa-
tients (5%). Cardi-O-Fix VSD occluder was the most commonly used
device (45%), Cardi-O-Fix PDA occluder (21%) and Amplatzer duct
occlude in 17% patients. Pre-procedural pulmonary artery systolic
pressure decreased signiﬁcantly from mean 81.12 mmHg to mean
43.17 mmHg post procedure over a mean follow-up of 18.5 months. No
residual shunt was found in 38 (90.47%) patients. Only two major
complications viz; severe aortic obstruction and symptomatic com-
plete heart block were noticed.
